Monocytosis as a marker of cardiovascular risk in patients with chronic kidney disease

• Grant number: 13/07966-8
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): July 01, 2013
• Effective date (End): June 30, 2014
• Field of knowledge: Health Sciences - Collective Health - Public Health
• Principal Investigator: Gilson Fernandes Ruivo
• Grantee: Luis Fernando de Carvalho Lopes
• Host Institution: Pró-Reitoria de Pesquisa e Pós-Graduação. Universidade de Taubaté (UNITAU). Taubaté , SP, Brazil

Abstract

Chronic Kidney Disease (CKD) is classified according to the glomerular filtration rate and is characterized by progressive and irreversible loss of kidney function, and in the final stage begins to renal replacement therapy. It is a public health problem worldwide due to clinical impact and associated mortality. Patients with CKD have systemic inflammation and immune deficiency is a chronic condition that causes oxidative stress and immune dysfunction with monocyte activation, cytokine production, and generation of reactive oxygen species. Chronic inflammation is associated with atherosclerosis, which promote increased endothelial permeability to LDL and monocytes with vascular structural changes, reduced blood flow, causing diseases such as coronary heart disease. This scenario inflammatory and atherosclerotic promotes a higher rate of cardiovascular disease (CVD), which is the main cause of mortality in CKD, both in dialysis nephropathy as not to dialysis. Given the role of monocytes in the pathogenesis of atherosclerosis and its function in the process of chronic inflammation suggest its use as a marker of cardiovascular risk (CVR), because previous studies have associated monocytosis as independent risk marker for CVD disease and brain ischemic vascular. The objective of this study is to evaluate the monocyte marker of cardiovascular risk factors in CKD, among others. With the approval of the Ethics Committee of the Institution will be made a retrospective study of 300 patients with CKD not on dialysis. Will be collected clinical and laboratory data to evaluate the metabolic profile and inflammatory cardiovascular risk. Be considered significant p <0.05. (AU)